DÄ internationalArchive39/2006Outpatient Care for Osteoporosis Patients in Germany – Results of the BoneEVA Study

Original article

Outpatient Care for Osteoporosis Patients in Germany – Results of the BoneEVA Study

Dtsch Arztebl 2006; 103(39): A-2542

Häussler, B; Gothe, H; Mangiapane, S; Glaeske, G; Pientka, L; Felsenberg, D

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.

1. Siggelkow H, Hufner M: Prevention of osteoporosis – Why? Who? How? Med Klin 1995; 90: 639–44. MEDLINE
2. DAGO: Die Empfehlungen der Deutschen Arbeitsgemeinschaft Osteoporose. Klin Pharmakol Aktuell 1998; 9: 47–53.
3. O'Neill TW, Felsenberg D, Varlow J, Cooper C, Kanis JA, Silman AJ: The prevalence of vertebral deformity in European men and women: the European Vertebral Osteoporosis Study. J Bone Miner Res 1996; 11: 1010–8. MEDLINE
4. Berufsverband der Fachärzte für Orthopädie: Weißbuch Osteoporose. Empfehlungen zur Diagnostik und Therapie der Osteoporose zur Vermeidung osteoporotischer Frakturen. Berlin: BVO 2004.
5. Dewitz HD: Osteoporose-Diagnostik, Prävention und Therapie. KV-Blatt 2004; 11.
6. Kanis JA, Delmas P, Burckhardt P, Cooper C, Torgerson D: Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease. Osteoporos Int 1997; 7: 390–406. MEDLINE
7. Lippuner K, von Overbeck J, Perrelet R, Bosshard H, Jaeger P: Incidence and direct medical costs of hospitalizations due to osteoporotic fractures in Switzerland. Osteoporos Int 1997; 7: 414–25.1 MEDLINE
8. Cranney A, Waldegger L, Zytaruk N et al.: Risedronate for the prevention and treatment of postmenopausal osteoporosis. Cochrane Database Syst Rev 2003: CD004523. MEDLINE
9. Cranney A, Tugwell P, Zytaruk N et al.: Meta-analyses of therapies for postmenopausal osteoporosis. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis. Endocr Rev 2002; 23: 524-8. MEDLINE
10. Papapoulos SE, Quandt SA, Liberman UA et al.: Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women. Osteoporos Int 2005; 16: 468–74. MEDLINE
11. Torgerson DJ, Bell-Syer SE: Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA 2001; 285: 2891–7. MEDLINE
12. Avenell A, Gillespie WJ, Gillespie LD, O'Connell DL: Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Syst Rev 2005: CD000227. MEDLINE
13. Shea B, Wells G, Cranney A et al.: Meta-analyses of therapies for postmenopausal osteoporosis. VII. Meta-analysis of calcium supplementation for the prevention of postmenopausal osteoporosis. Endocr Rev 2002; 23: 552–9. MEDLINE
14. Brecht JG, Schädlich PK: Burden of illness imposed by osteoporosis in Germany. Eur J Health Econom 2000; 1: 26–32.
15. Recker R, Gallagher R, MacCosbe P: Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clinic Proceedings 2005; 80: 856–61. MEDLINE
16. Penning-van Beest F, Goettsch W, Erkens J, Herings R: Persistence with bisphosphonate therapy and the impact of dosing frequency in patients with post-menopausal osteoporosis. Value in Health 2004; 7: 724.
17. Melton LJ: Osteoporosis: etiology, diagnosis and management. In: Riggs BL, Melton LJ, Hrsg.: Epidemiology of fractures. New York: Raven Press 1988; 133: 54.
18. AkdÄ: Therapieempfehlungen der Arznei­mittel­kommission der deutschen Ärzteschaft: Osteoporose. Arzneiverordnung in der Praxis 2003.
19. DVO: Osteoporose bei Frauen nach der Menopause und im höheren Lebensalter. Prophylaxe, Diagnose, Therapie-Empfehlungen des Dachverbandes der deutschsprachigen osteologischen Fachgesellschaften 2003.
20. Kanis JA, Dawson A, Oden A, Johnell O, de Laet C, Jonsson B: Cost-effectiveness of preventing hip fracture in the general female population. Osteoporos Int 2001; 12: 356–61. MEDLINE
21. Iglesias CP, Torgerson DJ, Bearne A, Bose U: The cost utility of bisphosphonate treatment in established osteoporosis. QJM 2002; 95: 305–11. MEDLINE
22. Kendler D, Kung AW, Fuleihan Gel H et al.: Patients with osteoporosis prefer once weekly to once daily dosing with alendronate. Maturitas 2004; 48: 243–51. MEDLINE
23. Miller NH: Compliance with treatment regimens in chronic asymptomatic diseases. Am J Med 1997; 102(2A): 43–9. MEDLINE
24. Tosteson AN, Grove MR, Hammond CS, Moncur MM, Ray GT, Hebert GM et al.: Early discontinuation of treatment for osteoporosis. Am J Med 2003; 115: 209–16. MEDLINE

Info

Specialities